ICD-10 Coding for Hodgkin Lymphoma(C81.0, C81.0N, C81.0V)
Comprehensive guide on ICD-10 coding for Hodgkin Lymphoma, including remission codes, documentation requirements, and common coding pitfalls.
Complete code families applicable to Hodgkin Lymphoma
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C81.0 | Nodular lymphocyte predominant Hodgkin lymphoma | Use when histopathology confirms nodular lymphocyte predominant subtype. |
|
| C81.1 | Nodular sclerosis Hodgkin lymphoma | Use when biopsy confirms nodular sclerosis subtype. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutHodgkin Lymphoma
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Hodgkin Lymphoma.
Using 'history of' instead of 'in remission'.
Impact
Clinical: Misrepresents current disease status., Regulatory: Non-compliance with coding guidelines., Financial: Potential for incorrect reimbursement.
Mitigation
Verify current disease status., Use remission codes appropriately.
Incorrectly coding FNA cytology without core biopsy.
Impact
Reimbursement: Incorrect coding may lead to denied claims., Compliance: Non-compliance with coding standards., Data Quality: Inaccurate clinical data representation.
Mitigation
Ensure FNA cytology is coded only if a core biopsy is performed.
Remission Coding
Impact
Incorrect use of remission codes.
Mitigation
Ensure documentation supports remission status.